Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.1946
https://www.valueinhealthjournal.com/article/S1098-3015(17)32280-5/fulltext
Title :
Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)32280-5&doi=10.1016/j.jval.2017.08.1946
First page :
A723
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1775